Arden regenerative care bay approved in fourteen further markets

LEIDEN, Netherlands, 30 October 2026

TriOptimum Medical Systems today announced that the Arden regenerative care bay has received regulatory approval in fourteen further markets, bringing the total to 31 countries. The approvals cover adult patients in critical care following severe trauma, burns or major surgery.

Arden combines a closed patient environment with automated monitoring of 46 physiological measures and a tissue-support system that adjusts temperature, humidity, oxygenation and wound perfusion continuously. Each bay is supervised by the clinical team responsible for the patient, who can override any automated setting from the bedside or the nursing station.

Since its introduction in 2021, Arden has supported more than 38,000 patient admissions in 186 hospitals. In a multicentre study published this year, patients treated in Arden bays after major burns spent a median of 4.6 fewer days in intensive care than a matched control group.

Arden is distinct from the regeneration bays installed at Citadel Station in 2019, which were supplied under a separate contract and are not sold to hospitals.

Clinicians judge a system like Arden on one thing: whether their patients go home as the people they were. Fourteen more countries have now looked at the evidence and agreed.

About TriOptimum

TriOptimum Corporation (NYSE: TRIO) is a diversified technology company with six business segments: Security Products, Medical Systems, Network Services, Orbital & Research Systems, Resources & Materials and Agrisystems. Founded in Halsworth, England, in 1951, TriOptimum employs 118,400 people in 47 countries and reported revenue of $41.27 billion in 2025.

Contacts